Not yet reviewed — this article is pending editorial review by Lyrea.

25b-NBOMe

Psychoactive Class

Chemical Class

25B-NBOMe is a synthetic psychedelic of the substituted phenethylamine class and a member of the 25x-NBOMe series. It is an N-benzyl derivative of 2C-B, first described by Ralf Heim at the Free University of Berlin. The substance had virtually no history of human use before appearing on the research chemical market in 2010. Compared to its parent compound 2C-B, 25B-NBOMe is reported to be approximately sixteen times more potent.

Dosage & Duration

Dosage

Threshold~50 µg

Light50-300 µg

Moderate300-500 µg

Strong500-700 µg

Heavy700+ µg

The blotter should be held under the tongue for 15 to 30 minutes to allow adequate absorption, as this compound has very low bioavailability when swallowed. Deaths have been reported at heavy doses.

Duration

Onset20-40 minutes

Come Up30-90 minutes

Peak4-6 hours

Offset2-4 hours

After Effects2-6 hours

Total8-12 hours

Subjective Effects

Effects vary widely by individual, dose, and context.

Physical

The physical effects of 25B-NBOMe can be broken down into six components all of which progressively intensify proportional to dosage.

Cognitive

The head space of 25B-NBOMe is described by many as remarkably light and underwhelming in comparison to the classical psychedelics. It is not uncommon for people to report feeling that their thought stream has maintained general normality in its specific style throughout low to moderate dosages. At high dosages however, mild to overwhelming cognitive alterations become present.

Acceleration of thought Time distortion Feelings of fascination, importance and awe Conceptual thinking Connectivity of thought Enhancement of current mind state Removal of cultural filter Ego suppression, loss and death

Visual

Distortions

Tracers After images Texture repetition Colour shifting Scenery slicing

Enhancements

Increased visual acuity Enhancement of colour Enhanced pattern recognition

Geometry

The visual geometry that is present throughout this trip is often described as similar in appearance to that of LSD. They can be comprehensively described as algorithmic in geometric style, intricate in complexity, fine and zoomed out in detail, fast and smooth in motion, structured in shape, colourful in scheme, glossy in colour, sharp around the edges and mostly rounded across their corners. In comparison to other more commonly used psychedelics they can be described as significantly more intricate than the visual geometry found within 2C-I and most of the 2C-x family in general as well as completely on par with LSD, Psilocin and DMT at appropriately high dosages. In terms of their behaviour, 25B-NBOMe's geometry leads onto Level 7A visual geometry with Level 7B remaining so far unconfirmed within this substance. They also seem to consistently build up in visual intensity when the tripper stares at a central point. This eventually envelops the visual field and creates the sensation that the tripper has broken through into a continuously shifting geometric landscape or structure with a vast sense of immersive physical size attributed to it.

Hallucinatory States

25B-NBOMe is capable of producing a full range of hallucinatory states within the level 1 - 3 range extremely consistently. However, level 4 hallucinatory breakthroughs are reported but very uncommon and inconsistent in comparison to other more commonly used psychedelics such as psilocin, 2C-E and DMT.

External hallucinations

Auditory

The auditory effects of 25B-NBOMe are common in their occurrence and exhibit a full range of effects.

Enhancements Distortions Hallucinations

Forked from Subjective Effect Documentation

by Josie KinsApril 2014.

Reagent Testing

Expected colorimetric results for common reagent tests. Colors show reaction change over 1–2 minutes.

Marquis(MQ)

Mecke(ME)

Mandelin(MD)

Liebermann(LB)

PROtestkit.eu

Pharmacology

Pharmacodynamics

25B-NBOMe is a selective serotonin 5-HT2 receptor agonist that acts as a potent partial agonist at the 5-HT2A receptor. It binds with high affinity to 5-HT2A, 5-HT2B, and 5-HT2C receptors, though the degree of subtype selectivity varies between studies: one reported similar affinity across all three subtypes (Ki = 0.5–1.7 nM), while another found 12- to 20-fold selectivity for 5-HT2A (Ki = 0.5 nM) over 5-HT2B and 5-HT2C (Ki = 10 and 6.2 nM, respectively). The compound is highly selective for 5-HT2 receptors over other serotonin receptors, monoamine receptors, and monoamine transporters (>200-fold). In rodent models, 25B-NBOMe increases cortical and subcortical levels of glutamate, serotonin, dopamine, and acetylcholine, with these elevations following an inverted U-shaped dose-response curve. It also acts as a low-potency partial agonist at rat and mouse TAAR1, though it is inactive at the human form of this receptor.

Pharmacokinetics

Absorption & half-lifenot documented yetMetabolitesnone documented yet

Interactions

Interactions not written up yet

An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.

Check

TripSit

Tolerance

Full Tolerance

Tolerance to the effects of 25B-NBOMe develops almost immediately after ingestion. This rapid tolerance buildup makes compulsive use essentially impossible, as subsequent doses within the tolerance window produce markedly diminished effects.

Baseline Reset

Approximately 2 weeks in the absence of further consumption

Half Tolerance

Approximately 1 week

Cross Tolerance

Psychedelics (all serotonergic psychedelics will have reduced effect following 25B-NBOMe consumption)

Harm Potential

Addiction & Dependence

Psychological

Low

25B-NBOMe has demonstrated reinforcing effects in rodent studies, producing conditioned place preference and self-administration with robust dopamine elevation in the nucleus accumbens. However, the rapid tolerance development that occurs immediately after ingestion makes compulsive use essentially impossible, and the substance is generally considered not habit-forming with desire to use often decreasing after experiences.

Toxicity

Cardiovascular

Vasoconstriction, tachycardia, and elevated blood pressure commonly occur during intoxication; in overdose situations these effects intensify significantly and may potentially result in organ failure or cardiac arrest.

Psychosis Risk

Overdose effects commonly include confusion, delusions, panic attacks, and aggressive behavior. These psychotomimetic effects appear dose-dependent and are more likely at higher doses.

Seizure Risk

NBOMes have shown a tendency to cause severe seizures, which are commonly reported among overdose symptoms. The substance appears to lower seizure threshold.

History & Culture

25B-NBOMe was first described in the scientific literature by Ralf Heim and colleagues at the Free University of Berlin, with initial findings presented in conference abstracts as early as 1999. The compound was subsequently characterized in more detail through continued research at the institution…

Legality

International

25B-NBOMe is listed in Schedule I of the Convention on Psychotropic Substances of 1971.

By Country

United StatesIllegalSchedule I

Controlled Substances Act³⁶

Placed in Schedule I of the Controlled Substances Act by the DEA in November 2013 using emergency scheduling powers, alongside 25I-NBOMe and 25C-NBOMe. Manufacturing, purchase, possession, processing, and distribution are prohibited.

BelgiumIllegalAnnex IIA

Royal Decree of 6 September 2017 regulating narcotic and psychotropic substances²³

25B-NBOMe is listed by name in Annex IIA, Belgium's list corresponding to Table I of the 1971 Convention on Psychotropic Substances. The Royal Decree applies to listed substances and requires prior authorization for import, export, transport, manufacture, possession, sale, supply, or acquisition. Authorizations are limited to scientific or medical purposes; for Annex IIA substances they are only available for scientific or very limited medical purposes through duly authorized medical or scientific establishments.

CanadaIllegalSchedule III

Controlled Drugs and Substances Act⁷

Controlled under Schedule III of the Controlled Drugs and Substances Act as of October 31, 2016. Classified as a derivative of 2,5-dimethoxyphenethylamine.

Czech RepublicBanned

Prohibited substance under Czech drug legislation.

FinlandIllegalSchedule I narcotic

Government Decree on substances, preparations and plants considered as narcotics (543/2008), Annex II, Schedule I of the 1971 Convention⁹¹⁰

25B-NBOMe is listed by name and chemical name in Annex II, Schedule I of Finland's Government Decree 543/2008. The current 2025 amendment retains that listing. Finland's Ministry of Social Affairs and Health states that production, manufacture, import, export, transport, distribution, trade, handling, possession, and use of narcotics are prohibited, subject to specified medical, scientific, investigative, and control-purpose exceptions.

IndonesiaIllegalGroup I

Minister of Health Regulation No. 15 of 2025 on Amendments to the Classification of Narcotics (Berita Negara Republik Indonesia 2025 No. 989), promulgated 28 November 2025¹²

The official Ministry of Health text places 25B-NBOMe at item 67 of the Group I annex. Article 1(2) defines Group I as narcotics usable only for scientific development and not for therapy. Article 3 expressly repeals Minister of Health Regulation No. 7 of 2025, replacing the refuted instrument.

ItalySchedule ICitation needed

Classified as a Schedule 1 controlled substance under Italian drug legislation.

LatviaIllegal (analog/blanket ban)2-5-dimethoxyphenethylamines

Law on the Coming into Force and Application of the Criminal Law, Annex 2, II.11(1)¹⁵¹⁶

25B-NBOMe is covered by Latvia's generic I-list entry for 2,5-dimethoxyphenethylamines rather than being named individually. That entry covers compounds derived from 2-(2,5-dimethoxyphenyl)ethanamine, including ring substitution and substitution of one or two nitrogen hydrogens with an unsubstituted or substituted alkyl group. The I list comprises prohibited especially dangerous narcotic substances and equivalent psychotropic substances; the legal-circulation law prohibits their manufacture, import, export, distribution, possession, acquisition, use, and transit.

New ZealandSchedule 2Citation needed

Controlled as a Schedule 2 substance under the Misuse of Drugs Act.

PhilippinesIllegalSchedule I

1971 Convention on Psychotropic Substances, Schedule I (Philippine scheduled controlled-substances list)¹⁹

25B-NBOMe is listed by the Philippine Dangerous Drugs Board in the Schedule I substances of the 1971 Convention on Psychotropic Substances. The Board's current scheduled controlled-substances list gives its chemical name as 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine.

PortugalIllegal25B-NBOMe or 2C-B-NBOMe

Decreto-Lei n.º 15/93, de 22 de janeiro, Tabela II-A, as republished by Lei n.º 23/2025, de 7 de março²³

Lei n.º 23/2025 republished the current Tabela II-A annexed to Decreto-Lei n.º 15/93 and expressly includes this substance. The table also covers its salts where possible and specifically designated isomers.

SingaporeIllegal25B-NBOMe and positional isomers

Misuse of Drugs Act 1973, First Schedule, Part 1 (Class A drugs), paragraph 18(13)^242526272829

25B-NBOMe is currently specified as a Class A controlled drug in Part 1 of the Act's First Schedule. The Act defines a controlled drug to include a substance specified in that Schedule and makes trafficking in a controlled drug an offence except as authorised. The current Fourth Schedule to the Misuse of Drugs Regulations independently lists the same substance and positional-isomer coverage as a controlled drug subject to specified regulatory requirements. The 2018 Act amendment and the parallel Regulations amendment both commenced on 1 May 2018.

SwedenIllegal25B-NBOMe

Förordning (1992:1554) om kontroll av narkotika, bilaga 1, gällande t.o.m. SFS 2026:1109³¹

The current official consolidated text states in 2 § that substances in bilaga 1 are to be considered narcotics under narkotikastrafflagen (1968:64). Bilaga 1 expressly lists the designated substance and alias.

ThailandIllegalCategory I

Table of Controlled Narcotic Drugs under Narcotics Code B.E. 2564 (2021)³⁴

Thailand's Food and Drug Administration lists 25B-NBOMe in its Table of Controlled Narcotic Drugs under the Narcotics Code. The table places it in Category I.

United KingdomIllegalClass A

Misuse of Drugs Act 1971³⁵

Controlled as a Class A substance under the Misuse of Drugs Act 1971 through the N-benzylphenethylamine catch-all clause. Class A carries the most severe penalties for possession and supply.

AustriaIllegalAnhang V.1

Suchtgiftverordnung; Suchtmittelgesetz¹

Prohibited under the Suchtmittelgesetz (Narcotic Substances Act) since June 26, 2019. Possession, production, and sale are illegal.

BrazilIllegal25B-NBOMe

Portaria SVS/MS nº 344, de 12 de maio de 1998, Anexo I, Lista F2, Atualização nº 101, published by RDC ANVISA nº 1.036, de 9 de julho de 2026⁴⁵⁶

The current consolidated Anexo I is Atualização nº 101 under RDC ANVISA nº 1.036/2026. It retains 25B-NBOMe in Lista F2; Lista F is headed ‘LISTA DAS SUBSTÂNCIAS DE USO PROSCRITO NO BRASIL.’ RDC nº 970/2025 is the preceding consolidated republication, not the current instrument.

ChinaControlled substanceCitation needed

Designated as a controlled substance as of October 2015 under national drug control regulations.

DenmarkIllegal (analog/blanket ban)Phenethylamine group

Bekendtgørelse om euforiserende stoffer (BEK nr. 405 af 26/03/2026), bilag 1, liste B, nr. 460⁸

25B-NBOMe is covered by Liste B's phenethylamine group: the definition includes N-(methoxybenzyl)-2-phenylethan-1-amine derivatives with alkyl, alkoxy, alkandiylbis(oxy), or halogen ring substitutions. Liste B substances may only be used for medical and scientific purposes; their import, supply, manufacture, possession, and other activity are subject to the order's controls and permissions.

GermanyIllegalAnlage I

Betäubungsmittelgesetz¹¹

Controlled under Anlage I of the Betäubungsmittelgesetz (Narcotics Act) since December 13, 2014. Manufacturing, possession, import, export, purchase, sale, procurement, and dispensing without license are prohibited.

IrelandIllegalSchedule 1

Misuse of Drugs Regulations 2017 (S.I. No. 173 of 2017)¹³

25B-NBOMe is listed in Schedule 1 of the Misuse of Drugs Regulations 2017. The Regulations prohibit production, supply, import and export of a controlled drug except as authorised, and limit lawful possession to specified exemptions.

JapanIllegalNarcotic

Cabinet Order Designating Narcotics¹⁴

Designated as a narcotic drug under Japanese law, effective November 1, 2015.

NetherlandsIllegalLijst I

Opiumwet¹⁷

25B-NBOMe is named in Lijst I of the Opiumwet. Article 2 prohibits importing, exporting, preparing, processing, selling, supplying, transporting, possessing and manufacturing substances in that list except where the Act provides an exemption or authorisation.

NorwayIllegal2C-B-NBOMe

Forskrift om narkotika (narkotikaforskriften), narkotikalisten¹⁸

25B-NBOMe is listed under the synonym 2C-B-NBOMe in Norway's narcotics list. The listed chemical name identifies the substance as 2,5-dimetoksy-4-brom-N-(2-metoksybenzyl)fenetylamin, so the listed name and chemical name cover this substance.

PolandIllegal25B-NBOMe

Rozporządzenie Ministra Zdrowia z dnia 17 sierpnia 2018 r. w sprawie wykazu substancji psychotropowych, środków odurzających oraz nowych substancji psychoaktywnych, załącznik nr 1, część 1 (Substancje psychotropowe grupy I-P), poz. 10, as amended by Dz. U. 2025 poz. 598 and Dz. U. 2026 poz. 934²⁰²¹²²

25B-NBOMe is expressly listed at item 10 in Annex 1, Group I-P. The subsequent official amendments effective 22 May 2025 and 28 July 2026 identify the Group I-P items they alter (item 7 in 2025; item 96 and repeal of item 99 in 2026), not item 10; the listed 25B-NBOMe entry therefore remains in force after those amendments.

RussiaBanned

Prohibited as a narcotic drug since May 5, 2015 under Russian federal drug control legislation.

South KoreaIllegal25B-NBOMe

Enforcement Decree of the Narcotics Control Act, Annex 3³⁰

South Korea lists 25B-NBOMe as item 82 among psychotropic drugs under Article 2(3)(a) of the Narcotics Control Act. The Annex identifies it as 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine and applies the listing to its salts, isomers, and salts of isomers.

SwitzerlandIllegalList d

Betäubungsmittelverzeichnisverordnung (BetmVV-EDI), Anhang 1 (Verzeichnis d)³²³³

25B-NBOMe is listed by name and chemical name in Verzeichnis d of the Swiss Betäubungsmittelverzeichnisverordnung. Switzerland treats Verzeichnis-d substances as prohibited narcotics; import, cultivation, manufacture, and marketing require a Federal Office of Public Health exception permit unless a stated statutory exception applies.

TurkeyIllegal

Classified as a controlled drug. Possession, production, supply, and import are prohibited.

References

Citations

Automated synthesis
Information aggregated and synthesized using an autonomous workflow built by Josie Kins.

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the 25b-NBOMe article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Wish to give generalised feedback? You can do so here.